CN113349254A - 抗氧化、调节血压的副干酪乳杆菌et-22及其应用 - Google Patents
抗氧化、调节血压的副干酪乳杆菌et-22及其应用 Download PDFInfo
- Publication number
- CN113349254A CN113349254A CN202011348850.2A CN202011348850A CN113349254A CN 113349254 A CN113349254 A CN 113349254A CN 202011348850 A CN202011348850 A CN 202011348850A CN 113349254 A CN113349254 A CN 113349254A
- Authority
- CN
- China
- Prior art keywords
- lactobacillus paracasei
- regulating
- blood pressure
- milk
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000186605 Lactobacillus paracasei Species 0.000 title claims abstract description 53
- 230000001105 regulatory effect Effects 0.000 title claims abstract description 46
- 230000036772 blood pressure Effects 0.000 title claims abstract description 29
- 239000003963 antioxidant agent Substances 0.000 title claims description 31
- 230000003078 antioxidant effect Effects 0.000 title claims description 30
- 230000003647 oxidation Effects 0.000 claims abstract description 21
- 238000007254 oxidation reaction Methods 0.000 claims abstract description 21
- 230000000694 effects Effects 0.000 claims abstract description 19
- 239000000839 emulsion Substances 0.000 claims abstract description 18
- 239000000203 mixture Substances 0.000 claims abstract description 18
- 235000013305 food Nutrition 0.000 claims abstract description 10
- 238000004321 preservation Methods 0.000 claims abstract description 5
- 238000000855 fermentation Methods 0.000 claims description 38
- 230000004151 fermentation Effects 0.000 claims description 38
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 claims description 38
- 235000015140 cultured milk Nutrition 0.000 claims description 28
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 claims description 19
- JBYXPOFIGCOSSB-GOJKSUSPSA-N 9-cis,11-trans-octadecadienoic acid Chemical compound CCCCCC\C=C\C=C/CCCCCCCC(O)=O JBYXPOFIGCOSSB-GOJKSUSPSA-N 0.000 claims description 19
- 229940108924 conjugated linoleic acid Drugs 0.000 claims description 19
- 229960003692 gamma aminobutyric acid Drugs 0.000 claims description 19
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 claims description 19
- 235000013336 milk Nutrition 0.000 claims description 17
- 239000008267 milk Substances 0.000 claims description 17
- 210000004080 milk Anatomy 0.000 claims description 17
- 102000019197 Superoxide Dismutase Human genes 0.000 claims description 16
- 108010012715 Superoxide dismutase Proteins 0.000 claims description 16
- 235000013361 beverage Nutrition 0.000 claims description 15
- 239000000047 product Substances 0.000 claims description 15
- 239000007788 liquid Substances 0.000 claims description 14
- 239000011720 vitamin B Substances 0.000 claims description 12
- 235000019156 vitamin B Nutrition 0.000 claims description 11
- 238000002360 preparation method Methods 0.000 claims description 9
- 239000006228 supernatant Substances 0.000 claims description 8
- 239000005541 ACE inhibitor Substances 0.000 claims description 6
- 101710129690 Angiotensin-converting enzyme inhibitor Proteins 0.000 claims description 6
- 101710086378 Bradykinin-potentiating and C-type natriuretic peptides Proteins 0.000 claims description 6
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 claims description 6
- 239000000843 powder Substances 0.000 claims description 6
- 229930006000 Sucrose Natural products 0.000 claims description 5
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 5
- 239000007787 solid Substances 0.000 claims description 4
- 239000002537 cosmetic Substances 0.000 claims description 3
- 239000005720 sucrose Substances 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 235000020122 reconstituted milk Nutrition 0.000 claims description 2
- 239000000126 substance Substances 0.000 abstract description 10
- 239000003814 drug Substances 0.000 abstract description 4
- -1 feed Substances 0.000 abstract description 4
- 238000011160 research Methods 0.000 abstract description 4
- 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 description 20
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 20
- UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 description 18
- 238000000034 method Methods 0.000 description 13
- 239000000758 substrate Substances 0.000 description 13
- 238000002156 mixing Methods 0.000 description 9
- QIAFMBKCNZACKA-UHFFFAOYSA-N N-benzoylglycine Chemical compound OC(=O)CNC(=O)C1=CC=CC=C1 QIAFMBKCNZACKA-UHFFFAOYSA-N 0.000 description 8
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 241000894006 Bacteria Species 0.000 description 7
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 6
- 238000002835 absorbance Methods 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 238000001514 detection method Methods 0.000 description 6
- 235000020124 milk-based beverage Nutrition 0.000 description 6
- WQGWDDDVZFFDIG-UHFFFAOYSA-N pyrogallol Chemical compound OC1=CC=CC(O)=C1O WQGWDDDVZFFDIG-UHFFFAOYSA-N 0.000 description 6
- 150000003254 radicals Chemical class 0.000 description 6
- 206010020772 Hypertension Diseases 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 5
- 230000007760 free radical scavenging Effects 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 108010016268 hippuryl-histidyl-leucine Proteins 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 235000019197 fats Nutrition 0.000 description 4
- 239000004310 lactic acid Substances 0.000 description 4
- 235000014655 lactic acid Nutrition 0.000 description 4
- 239000011159 matrix material Substances 0.000 description 4
- 239000006041 probiotic Substances 0.000 description 4
- 235000018291 probiotics Nutrition 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 230000001954 sterilising effect Effects 0.000 description 4
- 235000013343 vitamin Nutrition 0.000 description 4
- 239000011782 vitamin Substances 0.000 description 4
- 229930003231 vitamin Natural products 0.000 description 4
- 229940088594 vitamin Drugs 0.000 description 4
- 235000008939 whole milk Nutrition 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 230000002292 Radical scavenging effect Effects 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 229930003270 Vitamin B Natural products 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 235000021001 fermented dairy product Nutrition 0.000 description 3
- 235000003599 food sweetener Nutrition 0.000 description 3
- 230000031700 light absorption Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 230000000529 probiotic effect Effects 0.000 description 3
- 229940079877 pyrogallol Drugs 0.000 description 3
- 235000020185 raw untreated milk Nutrition 0.000 description 3
- 235000020183 skimmed milk Nutrition 0.000 description 3
- 238000002798 spectrophotometry method Methods 0.000 description 3
- 239000003765 sweetening agent Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 2
- 241000219195 Arabidopsis thaliana Species 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 description 2
- 208000000453 Skin Neoplasms Diseases 0.000 description 2
- 101710143049 Succinate-semialdehyde dehydrogenase [NADP(+)] Proteins 0.000 description 2
- 101710089222 Succinate-semialdehyde dehydrogenase, mitochondrial Proteins 0.000 description 2
- 102100023673 Succinate-semialdehyde dehydrogenase, mitochondrial Human genes 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000006701 autoxidation reaction Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000004737 colorimetric analysis Methods 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 235000020121 low-fat milk Nutrition 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 201000000849 skin cancer Diseases 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000011726 vitamin B6 Substances 0.000 description 2
- CUKWUWBLQQDQAC-VEQWQPCFSA-N (3s)-3-amino-4-[[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2s,3s)-1-[[(2s)-1-[(2s)-2-[[(1s)-1-carboxyethyl]carbamoyl]pyrrolidin-1-yl]-3-(1h-imidazol-5-yl)-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-methyl-1-ox Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C1=CC=C(O)C=C1 CUKWUWBLQQDQAC-VEQWQPCFSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 102000005862 Angiotensin II Human genes 0.000 description 1
- 101800000734 Angiotensin-1 Proteins 0.000 description 1
- 102400000344 Angiotensin-1 Human genes 0.000 description 1
- 101800000733 Angiotensin-2 Proteins 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 101800004538 Bradykinin Proteins 0.000 description 1
- 102400000967 Bradykinin Human genes 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- CWYNVVGOOAEACU-UHFFFAOYSA-N Fe2+ Chemical compound [Fe+2] CWYNVVGOOAEACU-UHFFFAOYSA-N 0.000 description 1
- VTLYFUHAOXGGBS-UHFFFAOYSA-N Fe3+ Chemical compound [Fe+3] VTLYFUHAOXGGBS-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 description 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
- 244000199866 Lactobacillus casei Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 238000013494 PH determination Methods 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 206010042496 Sunburn Diseases 0.000 description 1
- 241001327916 Termitomyces albuminosus Species 0.000 description 1
- 108010093894 Xanthine oxidase Proteins 0.000 description 1
- 102100033220 Xanthine oxidase Human genes 0.000 description 1
- DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- ORWYRWWVDCYOMK-HBZPZAIKSA-N angiotensin I Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C1=CC=C(O)C=C1 ORWYRWWVDCYOMK-HBZPZAIKSA-N 0.000 description 1
- 229950006323 angiotensin ii Drugs 0.000 description 1
- 229940040526 anhydrous sodium acetate Drugs 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000006851 antioxidant defense Effects 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 229910021538 borax Inorganic materials 0.000 description 1
- QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 108091092356 cellular DNA Proteins 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 230000035487 diastolic blood pressure Effects 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- MGJZITXUQXWAKY-UHFFFAOYSA-N diphenyl-(2,4,6-trinitrophenyl)iminoazanium Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1N=[N+](C=1C=CC=CC=1)C1=CC=CC=C1 MGJZITXUQXWAKY-UHFFFAOYSA-N 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
- 235000019797 dipotassium phosphate Nutrition 0.000 description 1
- 238000007323 disproportionation reaction Methods 0.000 description 1
- 239000012154 double-distilled water Substances 0.000 description 1
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 201000005577 familial hyperlipidemia Diseases 0.000 description 1
- 229910001447 ferric ion Inorganic materials 0.000 description 1
- 229910001448 ferrous ion Inorganic materials 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000004817 gas chromatography Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000003779 hair growth Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 235000020778 linoleic acid Nutrition 0.000 description 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-N linoleic acid group Chemical group C(CCCCCCC\C=C/C\C=C/CCCCC)(=O)O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 239000009438 liyan Substances 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- WRUGWIBCXHJTDG-UHFFFAOYSA-L magnesium sulfate heptahydrate Chemical compound O.O.O.O.O.O.O.[Mg+2].[O-]S([O-])(=O)=O WRUGWIBCXHJTDG-UHFFFAOYSA-L 0.000 description 1
- 229940061634 magnesium sulfate heptahydrate Drugs 0.000 description 1
- 229940099596 manganese sulfate Drugs 0.000 description 1
- 239000011702 manganese sulphate Substances 0.000 description 1
- 235000007079 manganese sulphate Nutrition 0.000 description 1
- SQQMAOCOWKFBNP-UHFFFAOYSA-L manganese(II) sulfate Chemical compound [Mn+2].[O-]S([O-])(=O)=O SQQMAOCOWKFBNP-UHFFFAOYSA-L 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 238000009629 microbiological culture Methods 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 210000002464 muscle smooth vascular Anatomy 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 235000020939 nutritional additive Nutrition 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000033116 oxidation-reduction process Effects 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- 238000006864 oxidative decomposition reaction Methods 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 230000036581 peripheral resistance Effects 0.000 description 1
- 238000005502 peroxidation Methods 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- KJFMBFZCATUALV-UHFFFAOYSA-N phenolphthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2C(=O)O1 KJFMBFZCATUALV-UHFFFAOYSA-N 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000005080 plant death Effects 0.000 description 1
- LWIHDJKSTIGBAC-UHFFFAOYSA-K potassium phosphate Substances [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 235000010339 sodium tetraborate Nutrition 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- BSVBQGMMJUBVOD-UHFFFAOYSA-N trisodium borate Chemical compound [Na+].[Na+].[Na+].[O-]B([O-])[O-] BSVBQGMMJUBVOD-UHFFFAOYSA-N 0.000 description 1
- SWGJCIMEBVHMTA-UHFFFAOYSA-K trisodium;6-oxido-4-sulfo-5-[(4-sulfonatonaphthalen-1-yl)diazenyl]naphthalene-2-sulfonate Chemical compound [Na+].[Na+].[Na+].C1=CC=C2C(N=NC3=C4C(=CC(=CC4=CC=C3O)S([O-])(=O)=O)S([O-])(=O)=O)=CC=C(S([O-])(=O)=O)C2=C1 SWGJCIMEBVHMTA-UHFFFAOYSA-K 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 239000011708 vitamin B3 Substances 0.000 description 1
- 239000011727 vitamin B9 Substances 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
- 229940075420 xanthine Drugs 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
- A23C9/123—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt
- A23C9/1234—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt characterised by using a Lactobacillus sp. other than Lactobacillus Bulgaricus, including Bificlobacterium sp.
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/16—Agglomerating or granulating milk powder; Making instant milk powder; Products obtained thereby
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K10/00—Animal feeding-stuffs
- A23K10/10—Animal feeding-stuffs obtained by microbiological or biochemical processes
- A23K10/16—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions
- A23K10/18—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions of live microorganisms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/38—Other non-alcoholic beverages
- A23L2/382—Other non-alcoholic beverages fermented
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/385—Concentrates of non-alcoholic beverages
- A23L2/39—Dry compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/99—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Polymers & Plastics (AREA)
- Microbiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Food Science & Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Nutrition Science (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Anesthesiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Toxicology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Birds (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Cardiology (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Dermatology (AREA)
- Physiology (AREA)
- Animal Husbandry (AREA)
- Zoology (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
Claims (10)
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011348850.2A CN113349254B (zh) | 2020-11-26 | 2020-11-26 | 抗氧化、调节血压的副干酪乳杆菌et-22及其应用 |
CN202310017824.9A CN116195630A (zh) | 2020-11-26 | 2020-11-26 | 调节血压的副干酪乳杆菌et-22及其应用 |
CN202310062047.XA CN116195631A (zh) | 2020-11-26 | 2020-11-26 | 调节睡眠的副干酪乳杆菌et-22及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011348850.2A CN113349254B (zh) | 2020-11-26 | 2020-11-26 | 抗氧化、调节血压的副干酪乳杆菌et-22及其应用 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202310062047.XA Division CN116195631A (zh) | 2020-11-26 | 2020-11-26 | 调节睡眠的副干酪乳杆菌et-22及其应用 |
CN202310017824.9A Division CN116195630A (zh) | 2020-11-26 | 2020-11-26 | 调节血压的副干酪乳杆菌et-22及其应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN113349254A true CN113349254A (zh) | 2021-09-07 |
CN113349254B CN113349254B (zh) | 2022-11-29 |
Family
ID=77524548
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202310017824.9A Pending CN116195630A (zh) | 2020-11-26 | 2020-11-26 | 调节血压的副干酪乳杆菌et-22及其应用 |
CN202011348850.2A Active CN113349254B (zh) | 2020-11-26 | 2020-11-26 | 抗氧化、调节血压的副干酪乳杆菌et-22及其应用 |
CN202310062047.XA Pending CN116195631A (zh) | 2020-11-26 | 2020-11-26 | 调节睡眠的副干酪乳杆菌et-22及其应用 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202310017824.9A Pending CN116195630A (zh) | 2020-11-26 | 2020-11-26 | 调节血压的副干酪乳杆菌et-22及其应用 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202310062047.XA Pending CN116195631A (zh) | 2020-11-26 | 2020-11-26 | 调节睡眠的副干酪乳杆菌et-22及其应用 |
Country Status (1)
Country | Link |
---|---|
CN (3) | CN116195630A (zh) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113892651A (zh) * | 2021-10-08 | 2022-01-07 | 河北一然生物科技股份有限公司 | 一种复合益生菌制剂在抗氧化领域中的新应用 |
CN114752525A (zh) * | 2022-04-21 | 2022-07-15 | 广西壮族自治区水牛研究所 | 一种具有降血压作用的干酪乳杆菌及其应用 |
CN114903083A (zh) * | 2022-06-09 | 2022-08-16 | 陕西科技大学 | 一种生物活性肽益生菌发酵绵羊乳及其制备方法 |
CN115851520A (zh) * | 2022-11-09 | 2023-03-28 | 厦门元之道生物科技有限公司 | 一种副干酪乳杆菌及其应用 |
Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103060243A (zh) * | 2013-01-17 | 2013-04-24 | 福建省农业科学院农业工程技术研究所 | 一株副干酪乳杆菌副干酪亚种菌株 |
CN105400727A (zh) * | 2015-12-21 | 2016-03-16 | 南昌大学 | 一株具有抗氧化活性的副干酪乳杆菌及其应用 |
CN106071436A (zh) * | 2016-06-12 | 2016-11-09 | 中国食品发酵工业研究院 | 一种能够改善睡眠质量的芦笋发酵饮品及其制备方法 |
CN108283285A (zh) * | 2017-12-31 | 2018-07-17 | 深圳市金乐智能健康科技有限公司 | 一种糖尿病的理疗保健食品 |
US20200078421A1 (en) * | 2018-09-11 | 2020-03-12 | Direct Digital, LLC DBA Adaptive Health | Nutritional supplements and therapeutic compositions comprising probiotics |
CN110893195A (zh) * | 2019-09-30 | 2020-03-20 | 内蒙古伊利实业集团股份有限公司 | 一种具有缓解肠道炎症功能的副干酪乳杆菌et-22 |
CN110903995A (zh) * | 2019-09-30 | 2020-03-24 | 内蒙古伊利实业集团股份有限公司 | 具有促消化功效的益生菌食用组合物及食品 |
CN110960559A (zh) * | 2018-09-30 | 2020-04-07 | 内蒙古伊利实业集团股份有限公司 | 用于抑制口腔病原菌的乳酸菌菌株的食品、口腔清洁以及医药组合物 |
CN110964658A (zh) * | 2018-09-30 | 2020-04-07 | 内蒙古伊利实业集团股份有限公司 | 一种具有免疫调节功能的副干酪乳杆菌et-22 |
CN111304113A (zh) * | 2019-12-20 | 2020-06-19 | 佛山科学技术学院 | 一种副干酪乳杆菌副干酪亚种及其应用 |
-
2020
- 2020-11-26 CN CN202310017824.9A patent/CN116195630A/zh active Pending
- 2020-11-26 CN CN202011348850.2A patent/CN113349254B/zh active Active
- 2020-11-26 CN CN202310062047.XA patent/CN116195631A/zh active Pending
Patent Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103060243A (zh) * | 2013-01-17 | 2013-04-24 | 福建省农业科学院农业工程技术研究所 | 一株副干酪乳杆菌副干酪亚种菌株 |
CN105400727A (zh) * | 2015-12-21 | 2016-03-16 | 南昌大学 | 一株具有抗氧化活性的副干酪乳杆菌及其应用 |
CN106071436A (zh) * | 2016-06-12 | 2016-11-09 | 中国食品发酵工业研究院 | 一种能够改善睡眠质量的芦笋发酵饮品及其制备方法 |
CN108283285A (zh) * | 2017-12-31 | 2018-07-17 | 深圳市金乐智能健康科技有限公司 | 一种糖尿病的理疗保健食品 |
US20200078421A1 (en) * | 2018-09-11 | 2020-03-12 | Direct Digital, LLC DBA Adaptive Health | Nutritional supplements and therapeutic compositions comprising probiotics |
CN110960559A (zh) * | 2018-09-30 | 2020-04-07 | 内蒙古伊利实业集团股份有限公司 | 用于抑制口腔病原菌的乳酸菌菌株的食品、口腔清洁以及医药组合物 |
CN110964658A (zh) * | 2018-09-30 | 2020-04-07 | 内蒙古伊利实业集团股份有限公司 | 一种具有免疫调节功能的副干酪乳杆菌et-22 |
CN110893195A (zh) * | 2019-09-30 | 2020-03-20 | 内蒙古伊利实业集团股份有限公司 | 一种具有缓解肠道炎症功能的副干酪乳杆菌et-22 |
CN110903995A (zh) * | 2019-09-30 | 2020-03-24 | 内蒙古伊利实业集团股份有限公司 | 具有促消化功效的益生菌食用组合物及食品 |
CN111304113A (zh) * | 2019-12-20 | 2020-06-19 | 佛山科学技术学院 | 一种副干酪乳杆菌副干酪亚种及其应用 |
Non-Patent Citations (8)
Title |
---|
HONGYUN LU等: "Safety Evaluation of Bifidobacterium lactis BL-99 and Lacticaseibacillus paracasei K56 and ET-22 in vitro and in vivo", 《FRONTIERS IN MICROBIOLOGY》 * |
MEGHA BHATNAGAR等: "Lactobacillus paracasei CD4 as potential indigenous lactic cultures with antioxidative and ACE inhibitory activity in soymilk hydrolysate", 《JOURNAL OF FOOD MEASUREMENT AND CHARACTERIZATION》 * |
PEGAH HAMZEHLOU等: "Production of Vitamins B3, B6 and B9 by Lactobacillus Isolated from Traditional Yogurt Samples from 3 Cities in Iran, Winter 2016", 《APPLIED FOOD BIOTECHNOLOGY》 * |
SHEN-SHIH CHIANG等: "Beneficial effects of Lactobacillus paracasei subsp. paracasei NTU 101 and its fermented products", 《APPL MICROBIOL BIOTECHNOL》 * |
刘春晓等: "内蒙古锡林郭勒盟地区传统奶油制品中产共轭亚油酸乳酸菌的分离筛选与鉴定", 《食品科学》 * |
刘艺茹: "分离自人体肠道的副干酪乳杆菌K56和ET-22的菌株鉴定", 《食品与发酵工业》 * |
孟祥升等: "副干酪乳杆菌及其胞外多糖的抗氧化性研究", 《食品科技》 * |
张俊等: "副干酪乳杆菌的益生特性及其应用研究进展", 《包装与食品机械》 * |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113892651A (zh) * | 2021-10-08 | 2022-01-07 | 河北一然生物科技股份有限公司 | 一种复合益生菌制剂在抗氧化领域中的新应用 |
CN114752525A (zh) * | 2022-04-21 | 2022-07-15 | 广西壮族自治区水牛研究所 | 一种具有降血压作用的干酪乳杆菌及其应用 |
CN114752525B (zh) * | 2022-04-21 | 2022-09-09 | 广西壮族自治区水牛研究所 | 一种具有降血压作用的干酪乳杆菌及其应用 |
CN114903083A (zh) * | 2022-06-09 | 2022-08-16 | 陕西科技大学 | 一种生物活性肽益生菌发酵绵羊乳及其制备方法 |
CN114903083B (zh) * | 2022-06-09 | 2023-10-20 | 西安百跃羊乳集团有限公司 | 一种生物活性肽益生菌发酵绵羊乳及其制备方法 |
CN115851520A (zh) * | 2022-11-09 | 2023-03-28 | 厦门元之道生物科技有限公司 | 一种副干酪乳杆菌及其应用 |
CN115851520B (zh) * | 2022-11-09 | 2024-04-19 | 厦门元之道生物科技有限公司 | 一种副干酪乳杆菌及其应用 |
Also Published As
Publication number | Publication date |
---|---|
CN116195631A (zh) | 2023-06-02 |
CN116195630A (zh) | 2023-06-02 |
CN113349254B (zh) | 2022-11-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN113367191B (zh) | 用于抗氧化、调节血压的副干酪乳杆菌k56及其应用 | |
CN113349254B (zh) | 抗氧化、调节血压的副干酪乳杆菌et-22及其应用 | |
CN113773999B (zh) | 副干酪乳杆菌发酵滤液、制备方法及其应用 | |
Zhao et al. | Preventive effect of Lactobacillus plantarum KSFY02 isolated from naturally fermented yogurt from Xinjiang, China, on d-galactose–induced oxidative aging in mice | |
CN113930361B (zh) | 一种副干酪乳杆菌的发酵培养基及其应用 | |
CN111471604B (zh) | 单胞酿酒酵母菌ZLG-6和植物乳杆菌Picp-2的应用 | |
CN113350383B (zh) | 抗氧化、调节血压的乳双歧杆菌bl-99及其应用 | |
CN113413351A (zh) | 一种具有美白抗衰功效的发酵液、发酵多肽及其制备方法和应用 | |
CN108634298B (zh) | 黑果枸杞酵素及其制备工艺和用途 | |
CN116286468A (zh) | 一株具有抗氧化功能的发酵粘液乳杆菌lf-onlly及其在发酵食品中的应用 | |
CN114642686A (zh) | 一种复合益生菌及其延缓衰老和抗氧化的作用 | |
KR101984400B1 (ko) | 항산화 및 항피로 효능을 갖는 매실식초의 제조방법 | |
KR20110135477A (ko) | 항산화 및 미백 효능을 갖는 효모 발효액 및 이의 제조 방법 | |
Fidina et al. | The Effects of the Addition of Banana Puree to the Total Number of Total Probiotic Bacteria, pH Value and Organoleptic Characteristics of the Synbiotic Yoghurt Made from Goat Milk and Banana Puree | |
Long et al. | Free radical scavenging ability of soybean milk fermented by Lactobacillus plantarum YS4 isolated from yak yoghurt in vitro | |
CN112167345B (zh) | 含抗氧化的乳酸菌发酵物的食品组合物以及医药组合物 | |
CN113632922A (zh) | 一种溶胞物、以及制备方法与应用 | |
CN113549583A (zh) | 一种复合菌剂、应用以及利用复合菌剂制备藜麦发酵乳的方法 | |
Reshetnik et al. | Study of starter cultures in biotechnology of medical and preventive nutrition products | |
CN111528317A (zh) | 一种生态型火龙果汁凉茶饮料的制备方法 | |
TWI824330B (zh) | 經乳酸菌發酵之嘉寶果萃取物及其製備方法 | |
CN111500642B (zh) | 一种蓝莓发酵产物及其制备方法和应用 | |
CN115006340B (zh) | 一种抗氧化组合物及其化妆品、应用 | |
CN113974099B (zh) | 一种具有抗氧化活性的血橙发酵物的制备方法及其应用 | |
CN114081862B (zh) | 一种泛喜马拉雅地区青稞酒酒曲来源的酿酒酵母发酵产物制备及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
EE01 | Entry into force of recordation of patent licensing contract | ||
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20210907 Assignee: JINQIAO BIOTECHNOLOGY CO.,LTD. Assignor: INNER MONGOLIA YILI INDUSTRIAL GROUP Co.,Ltd. Contract record no.: X2023990000497 Denomination of invention: Antioxidant and blood pressure regulating Lactobacillus paracasei ET-22 and its application Granted publication date: 20221129 License type: Common License Record date: 20230515 |
|
CP02 | Change in the address of a patent holder | ||
CP02 | Change in the address of a patent holder |
Address after: 010000 No.1 Yili Street, Chilechuan Dairy Development Zone, Hohhot, Inner Mongolia Patentee after: INNER MONGOLIA YILI INDUSTRIAL GROUP Co.,Ltd. Patentee after: INNER MONGOLIA DAIRY TECHNOLOGY RESEARCH INSTITUTE Co.,Ltd. Address before: 010110 No.1 Jinshan street, Jinshan Development Zone, Hohhot, Inner Mongolia Autonomous Region Patentee before: INNER MONGOLIA YILI INDUSTRIAL GROUP Co.,Ltd. Patentee before: INNER MONGOLIA DAIRY TECHNOLOGY RESEARCH INSTITUTE Co.,Ltd. |